Therapeutic Targeting Of Tgf Beta Ligands In Glioblastoma Using Novel Antisense Oligonucleotides Reduces The Growth Of Experimental Gliomas

Purpose: Transforming growth factor (TGF)-beta is expressed at high levels by glioma cells and contributes to the malignant phenotype of glioblastoma. However, its therapeutic targeting remains challenging. Here, we examined an alternative therapeutic approach of TGF beta inhibition using two novel phosphorothioate-locked nucleic acid (LNA)-modified antisense oligonucleotide gapmers, ISTH1047 and ISTH0047, which specifically target TGF beta(1) and TGF beta(2).Experimental Design: We characterized the effects of ISTH1047 and ISTH0047 on TGF beta(1/2) expression, downstream signaling and growth of human LN-308, LN-229, and ZH-161 cells as well as murine SMA-560 glioma cells in vitro. Furthermore, we assessed their target inhibition and effects on survival in orthotopic xenogeneic and syngeneic rodent glioma models in vivo.Results: Both antisense oligonucleotides specifically silenced their corresponding target and abrogated SMAD2 phosphorylation in several glioma cell lines. Moreover, inhibition of TGFb1 or TGFb2 expression by ISTH1047 or ISTH0047 reduced the migration and invasiveness of LN-308 and SMA-560 glioma cells. Systemic antisense oligonucleotide administration to glioma-bearing mice suppressed TGFb1 or TGFb2 mRNA expression as well as the expression of the downstream target PAI-1 in orthotopic gliomas. Gliomabearing mice had significantly prolonged survival upon systemic treatment with ISTH1047 or ISTH0047, which was associated with a reduction of intratumoral SMAD2 phosphorylation and, in a fully immunocompetent model, with increased immune cell infiltration.Conclusions: Targeting TGFb expression with the novel LNA antisense oligonucleotides ISTH1047 or ISTH0047 results in strong antiglioma activity in vitro and in vivo, which mayrepresent a promising approach to be examined inhuman patients with glioma.